BIOGEN INC. (BIIB) — Current Report

AI-Powered SEC Filing Analysis

Latest Current Report Filed: 2026-05-14

Key Insights

Biogen completed the acquisition of Apellis Pharmaceuticals with a $2 billion term loan facility, demonstrating significant capital deployment for strategic growth in the ophthalmology market through SYFOVRE® acquisition.
The CVR agreement includes contingent milestone payments of up to $4.00 per share tied to SYFOVRE® net sales targets ($1.5B-$2B annually), creating upside potential if the drug meets commercial expectations but introducing execution risk.
Biogen secured favorable financing terms with a 364-day tranche at SOFR+0.75% and a two-year tranche at SOFR+0.75-1.0%, with a maximum consolidated leverage ratio covenant of 3.75x (expandable to 4.25x), indicating manageable debt structure post-acquisition.
The acquisition completion on May 14, 2026 adds a late-stage/approved ophthalmology asset to Biogen's pipeline, diversifying revenue streams beyond neurology but requiring successful commercialization to justify the acquisition price and debt taken on.

Want the newest filings?

This analysis covers the filing from 2026-05-14. New 10-K, 10-Q and 8-K filings are analyzed the moment they are released — exclusively in the app.

Download on the App Store Open in app →

Earlier Current Report filings

Filed: 2026-04-29

Biogen announced Q1 2026 financial results on April 29, 2026, representing routine quarterly earnings disclosure with the press release furnished as Exhibit 99.1 for investor review.
The filing is a standard 8-K submission for earnings results and does not indicate any material agreements, leadership changes, or significant corporate events that would materially impact the company.
The press release was furnished but not filed under SEC regulations, meaning it is not subject to Section 18 liability and was not incorporated by reference into other securities filings, which is typical for earnings announcements.

Filed: 2026-04-06

Biogen expects to incur approximately $34 million in acquired in-process research and development, upfront and milestone expenses in Q1 2026, impacting GAAP and non-GAAP earnings per share by $0.19.
The company does not provide financial guidance for such expenses due to the uncertainty of future transactions, indicating a lack of visibility into R&D spending.
The filing includes standard forward-looking statement disclaimers, highlighting the risks and uncertainties that could cause actual results to differ from estimates.

Filed: 2026-03-31

Biogen is acquiring Apellis Pharmaceuticals through a tender offer and subsequent merger, indicating Biogen's strategic focus on expanding its product portfolio and pipeline.
The acquisition will cost Biogen up to $45 per share of Apellis, consisting of $41 per share in cash and up to $4 per share in contingent value rights (CVRs) tied to future milestones.
The transaction is subject to customary conditions, including regulatory approval and a minimum tender threshold of more than 50% of Apellis' outstanding shares.

Filed: 2026-03-11

Biogen has announced the departure of its Chief Legal Officer, Susan H. Alexander, effective at the end of May 2026. The company has initiated a search to identify its next Chief Legal Officer.
The departure of the Chief Legal Officer may indicate changes in the company's leadership and strategy, which could have implications for investors.
Investors should monitor the company's progress in finding a new Chief Legal Officer and any potential impacts on the company's operations and financial performance.

Filed: 2026-02-11

The resignation of Caroline Dorsa, Chair of the Biogen Board of Directors, is not related to any disagreement with the company, indicating a smooth transition in leadership.
The Board has elected Dr. Maria C. Friere to serve as the new Chair, bringing in new leadership and potentially a fresh perspective.
The timing of this leadership change, prior to the Annual Meeting, suggests the company is proactively managing the transition and maintaining continuity for investors.

Other reports for BIOGEN INC.

Insider Trading Quarterly Report Annual Report

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.